Physician profile
David Collipp
NPI 1811080518
$1,714.43
in general payments reported to CMS, 2019-2025
21 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $55.00 · 2021: $214 · 2022: $230 · 2023: $367 · 2024: $337 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $806.37 | 2022-2025 | Botox, Ubrelvy |
| Allergan, INC. | $213.39 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $181.28 | 2022-2024 | Xeomin |
| Scilex Pharmaceuticals INC. | $89.54 | 2019 | |
| Eisai INC. | $44.98 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $38.87 | 2021 | |
| Ibsa Pharma INC. | $36.96 | 2023 | Tirosint, Licart |
| Vanda Pharmaceuticals INC. | $36.76 | 2023 | Fanapt, Hetlioz |
| Vertex Pharmaceuticals Incorporated | $34.56 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $32.40 | 2019-2020 | |
| Medline Industries Lp | $26.63 | 2019-2022 | |
| Lundbeck LLC | $21.67 | 2025 | Vyepti |
| Ipsen Biopharmaceuticals, INC | $20.12 | 2022 | |
| Nalu Medical, INC. | $19.91 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.57 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Piramal Critical Care | $19.26 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.78 | 2021 | |
| Mdd US Operations, LLC | $15.47 | 2022 | |
| Biodelivery Sciences International, INC. | $14.48 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.23 | 2024 | Quviviq |
| Lilly USA, LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Collipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.